TNFRSF17 and plasma cell myeloma: DREAMM-5 (NCT04126200) contains multiple substudies to evaluate different Belamaf-containing combinations, including the T-cell activating checkpoint mAbs GSK3359609 and the GS inhibitor nirogacestat which increases BCMA level on the myeloma cell surface [71].